Continuous Double Ovarian Stimulation.

• Status: Recruiting
• Trial end date: 2023-05-30
• Target enrollment: 0
• Participant gender: Female

Summary

To evaluate the efficacy of the weekly use of corifollitropin alfa in double ovarian stimulation process and to compare it to the conventional protocol with daily medication administration.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Instituto Bernabeu
• Treatments: Follicle Stimulating Hormone; Hormones

Criteria

Inclusion Criteria:

• Patients with indication for DUOSTIM protocol

• Maximum age of 43 years (up to one day before their 44th birthday) at the beginning of the stimulation process.

• Ability to participate and comply with the study protocol.

• To have given written consent

Exclusion Criteria:

• Finding of ovarian pathology at the time of initiation of stimulation: e.g. ovarian cysts.

• Concurrent participation in another study.